Nuplazid Significantly Delays Relapses in Dementia-related Psychosis, Phase 3 Study Shows

Nuplazid Significantly Delays Relapses in Dementia-related Psychosis, Phase 3 Study Shows
Treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in people with dementia-related disorders such as Alzheimer’s and Parkinson’s diseases, according to results from the ongoing Phase 3 HARMONY study. Evaluation by an independent data monitoring committee recommended an early stop to this trial based on the treatment’s “robust” efficacy, Acadia Pharmaceuticals, Nuplazid’s manufacturer, announced in a press release. The study’s primary goal — that of a statistically significant longer time to a psychosis relapse — was met in this early analysis. The findings will be presented by Erin Foff, MD, PhD, Acadia's clinical director, at the upcoming 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, which will take place Dec. 4-7 in San Diego. The late-breaking oral presentation will be titled “HARMONY Relapse-Prevention Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis.” Nuplazid is a selective serotonin inverse agonis
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *